Connect with us

Business

Cannabis Pharmaceuticals Inc. (OTCMKTS:CNBX) Initiates Expansion Of Its Cannabinoid Diagnostic Platform Tests In Europe

Published

on

Cannabis Pharmaceuticals Inc. (OTCMKTS:CNBX) commenced expansion in the European markets to offer cancer patients tailored cannabinoid treatment tests based on the company’s diagnostic platform in jurisdictions where regulations allow.

HTS diagnostic platform helping in tailoring cannabinoid treatments

This comes as the number of European countries permitting the medicinal use of cannabis products continues to grow each day. The increasing number of cancer patients in Europe that need cannabinoid treatments also necessitated the company’s move. Cannabis Pharmaceuticals is strategically focusing its efforts to ensure its HTS diagnostic platform is accessible across the continent. The company intends to carry out more clinical studies so that it can meet this milestone.

Cannabis Pharmaceutical’s HTS diagnostic platform uses the Israeli-based High Throughput Screening facility for the trials. The platform is designed for patients with cancer seeking optimal cannabinoid composition. The test involves getting cancer cells and screening them against various cannabinoid compositions offered in the patient’s jurisdiction. After exposing the cancer cells to cannabinoid compositions they are then monitored for necrotic and apoptotic effects. They then send the results to the patients and physicians to help pick appropriate cannabinoid therapy that can offer optimal results.

There is a massive opportunity in Europe from cannabinoid therapies

World Health Organisation issued a report last year indicating that over 58,000 colorectal cancer cases were reported annually in Germany. As a result, based on previous pre-clinical results that showed differential necrotic effects on colorectal cancer cells using Cannabinoids, the company has moved to expand its penetration in Europe. The focus will be on gastrointestinal tract cancer patients.

The company was delighted to expand its reach in Europe to countries where it is legal to sell medicinal cannabis products. Chairman and Co-Founder, Itamar Borochov added that the company aims to offer valuable insights for tailoring cannabinoid-based treatment for cancer patients. He added that there is a massive opportunity in European markets as more countries allow medicinal use of CBD and THC products.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.